{"id":832239,"date":"2025-04-01T07:26:08","date_gmt":"2025-04-01T11:26:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/"},"modified":"2025-04-01T07:26:08","modified_gmt":"2025-04-01T11:26:08","slug":"celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/","title":{"rendered":"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MINNEAPOLIS, April  01, 2025  (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: <a href=\"https:\/\/wsw.com\/webcast\/stifel99\/celc\/2065375\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/wsw.com\/webcast\/stifel99\/celc\/2065375<\/u><\/a>; and<\/li>\n<li>A fireside chat at the 24<sup>th<\/sup> Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: <a href=\"https:\/\/wsw.com\/webcast\/needham146\/celc\/2212811\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/wsw.com\/webcast\/needham146\/celc\/2212811<\/u><\/a>.<\/li>\n<\/ul>\n<p>Alternatively, the live webcasts will be accessible from the Investors section of the company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cy3RvEgKcsrGfApF11sCkCZCgHdlRKvv3WVT-r6z2RB3GanOybG63V0Y6Ugf-N6RRqBh3GoK7FMCEA5d3g9XPZp-9xeuGlx_UJq3n6ZXuSLny81OzX7KjflBenRFjhZiCqe1aQQvs_9yiWwm14XZ8eWMq_lUtZHXqlFotjI4g_M=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/ir.celcuity.com\/events-presentations\/<\/u><\/a> with a replay available shortly after the live events.<\/p>\n<p>\n        <strong>About Celcuity<\/strong>\u00a0<\/p>\n<p>Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company&#8217;s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1\/2 inhibitor that comprehensively blockades the PI3K\/AKT\/mTOR (\u201cPAM\u201d) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K\u03b1, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+\/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2rrKYJRDIsPm1_Gb3MSmSziXmhMCWLDuU61-uIZJ6heIujA_HOxXx7IfsN1bXVhmYXPTkb__ndC59kP8RRFRRRN8Mf5uHdo2gBGlfuVNXQjTA5CHGeDU5Bfitm2SwzCuUje7z2TBRtJcUEJ6SSqwwvvLiG2Vi4OPjHseY1HoKeHP_fgcLAxMMRBGPEsSR7L2SbsM5jq8vQkqFTABR9omD9PnDOFRtJScIwkJj85iuKonkT8OEIl7ay0-1uR3-FLODtERtO5_-H5ez0Zr39N0PxvzoE2ct0AGndcv17vpLb9iuYNl6hMifr6GQMaIj75uYkvSUuv44VuYSA9tUAr3i-0-y_tE-jmaRvhFKSXKdP_v8DksmwXCLHq48jIq1_VWTVp1ixULYkCNGnid8QCwsbwLu9bMqvP-3kMfg5UNc2UT3EZ4AUsqzKO6I13WEp_RmWBKBwRmIyi9KXawoxfSJe6hNarL7sYjHXA0e7rWeJXcbqdKR23xY-Shp9DCzimUnqcF78b1gOonG1M1UZWqSdaXoi1x-gx74JLkvm36tnV-UjDAeDPknEcfkmH_x_57b8xVfRnK0omolOhMWUl-0WNxlqSFPfy0IEdoQWnwT292TP1uBFqtjfwpyqhpPiKC_2uyZc39228ol6qq-fFhI62k1a-ggz86Br9W5EGH8TgX5KfddIrBAbyYMv_BWGsRrEwVJGazfuPbnI5yl2-r9-Z2AS8GXgwiR3qmOKf5b030mh4E2Fsdn8QKoWM5dsvlc02ZI02DwZDlTL2HirJZ5twbXsFJtTJ-0umedl-sciP2K5UJ-ffy0ejDb3KEg0mCU-Nal_vBHwZEZmKR9JbOcu2CF6u-GftyXnO3QXzx8mmZLriJ46g_Xad7tXb_3Z8iA_mSqs1_dqzcD6O7G-VVKwVecmNowIiWcYjd9O2BTLl4K4U3tycru5MBw8ew6xI1xB6ZS4s4s9K-dnCE376AXZU8ylKjumTLCx3gNYrDbcZfYkw5SqH7ms2E5loRVWKTbAVocMupvyIR3eacX7ze8e5cdJyFv37OnOJejnW9qn48SSK_7yC5xFD_sCubxsTtwZ-jmDXsP9WO3VtBqCbsEqfQ9RyyXgxot6mc2zMDlEDrPmiAwUxpZu-k7nw_26jTLiJDWTyyabHjae3277SOee0th-KrXsumyDy3hXV69FLAi3WACE8tlaOqW9y1RUxSMs64u5pOssMP6KuxuOXXxvc6Ft_oA8yRE_BasfKgFY1ADK0z8Jf6Kzwh6lnbNnULz6E1PjcrpqNvs6wLJpsfPFWxmLbafT6ap8jJYdhYVDAxn3bmibCrLQrIkEZVkh-Vpb--ImC9QY5oWkrJSffi5Gn_CpNU7ulmLq2uWx6boXd8AvDc9y3b2mSVextUq3y00eDXsPu4GnizGDTnVUZk-NZXD3WPZGEbVp0n4Z-Vtv-_AF686evSyAjpLWrYc0aR13-4Hjx5E1CPUbJM8NIDs5t17Z-9z2Y9Vol9dMNnLEsadkqtUbdgJ1ay_LnP1-5zSafI6S-E4tFcbHq2KJ0sRWBrDeaxyFGiNRdjehKETwd7EHkcjUK2evFsdU8MjOAj4mYUR3eOXdTtXlRVnHaOtK7qeUWTplIhoDDrKBcy7CUv0AQWtwnBiipdpaBwP__ZpP9LwAJLvRuCIWBS3BsVqA==\" rel=\"nofollow\" target=\"_blank\"><u>ClinicalTrials.gov<\/u><\/a>. A Phase 1b\/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4\/6 inhibitor and fulvestrant as first-line treatment for patients with HR+\/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9dJVQCtmKzve4CUnXo3hmPnX5tKetu72uQ9qwduuPXRlSWcTCVW04N7BjPAYQOt0_u_aMJaekgkwW_kkyvQdvMu_TF9M-iKP3hBQGmclqoAo6UF5VUJxaupD0FEt2aEQw9e9i1_0WHfKy0yEpec_D5VZduGcOwqMJFw__-DE0ZkfZS1BedycK_gW8v7R509XOirCieODzNQCK5RYZ3wdjd3d-ygYr7fzfhPXahVB2CktilZeTmF7OKR-3TxopTcmneJQ7P65LZE-Ql-KD12KNkAMfPYziUsuWMZfoX5Sj-6P-_rFV_1gfRvYqg8ZWoB00gIKy79EuR-Vd9BqeQI6nB8a43vPq5K_BzVQOHjDwxwP4WAWKl3zH9Acw3O-PL-DEMrZ6MRK3KL9DPfSUnZhG4x7_zPcb4rGGIDIQGp6GgHTawa6jJoy3BHzU_Rf1VkgVPdLGeyJMQQYFaT3tk_pk9iMdX4e3akXFP8mY207VaB4YR_yAe2TmlB2ndiygKSiuGUCaPScFE3bopzbnYr25_sqmpQzyB6E8N5H04c63a6rLdudchWHRFsaxOFAxmRMoXhPOO0OM9iJ4fohKcNNrGalKoD-7dgA8Xsmpg2ramC4xXoaT7cQs04gw11iT5v8iEbsdG0cJ2N7VEskhS1ZNPmMm_F-dzjRDeIfJpufsfKSBS7jZnE4_0nu3b3BxTML84HMnHCTd_BvP2R7pVghHzZw2mhuCES2cRNeijJ1KE-Um2rMAOTab8v6pho4-FEPGu1ibeGFhiWCrfJZp3sKiYSipuytEcigcKSppNBchdZt7x9DisTWtzOnax1HDsuGf_ugfsOdEFRMaGPCZv0t-uqwuJEfpF_Jzx8jar-Mm9tqBX369SOU2oNuyusNV8LGvZzm-VG_SWcbB9mlHUeDYfIFt-00CU33zWJeI-IMEeAqLnsmw-WiM9EnEO3___IS6f1c7dseXFHOT1kXcJwa0bPkMgUAqL6HwAtUqjpXyf8KtV6rSQFha55Ve27p6n9gFEhW0m6lDlNDWFk3xv70erkM1ssIS3ynDyFOEyL5LS2EWtn8icp-xbXQBBuY-Gr8sygbSo1u2R-e4M4OWiHukzhZS_zRla2WTF1RKwpUnuI3p71K5g5H3VB__H9UDVSoakD0drNbp7rBNsbTrvzAF2y4Nkfeo_9wa9694JC1Q4-QvjMlOLBsu0vIsMrtcL3-x5hLKogxQEwBqdTsd4QBKkmEno7aJHZ-GSBWpDVqXxHc3Fb8eIgiMUF9-IBj6jM0DgQcRyKd-5w_3ufsprXUfw-a1lwc8YrCURn-LWqzfrgWXEdbBfC63o48XIu-l9vRQUrzLLi6zLB1PecPkRtHdzvI1GKxsxqn0uy-Q2AfU555ZoS5z3gwwjXBbRNbhfK0-QKCVUHIYdhRnM_F3p4-sy9ZmUkUW2XtGrGzafGDUI-Im3quh6i0z1nt45Dcg1DQrSf8LVQthfEwf6y-hxgu5_-DFfPhO8dtwy-0Z1h4z58=\" rel=\"nofollow\" target=\"_blank\"><u>www.celcuity.com<\/u><\/a>. Follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8FU6pGi7AXuJHqA2es8riy2kfaY3QXMvf2OyhOI7u8ze2t6osrO0YHQV5CCywvBpK9tzaBUFBgcaLOduJHiJOxq986k9GnC-yacCAcKMgYAxU3wheC3lKx36KDrcNXrcPCCML1M3wKkWi9rCUzBW2F9eOGRFX0zkkKysG0xv3ZOO6oEWYfnY7ekiH5FIEbrMSYCS34MV2oIGRJNDGdtsN4Lxpu-Dyf9sr9LchHwocRhYELQr165kBf5IkffYyleh2CjvQEExoOk-z6zzYdIrqiftP3hdAx_sovidE4ggLObdmrEfjOovWghOBF1mj8jWNHWJNxQ480C-x9-bFxtMsuR4MjbyD9Iy_OluUVjjrPu0BzAXXbD2cDWcxiZWmNZg333EAyDlVD-QHKspNa-A0-JFm82zaH_ASiNbhUHZ5XEa83edd6_mq0PHcBgq6rWRksBlzNMYtTwJUr8ev-Qt6Oqqfl5R-rWroCphsslNsH6lcccwQqZ4TvqAs6mcZ3prT_oBgnErugV2qdCBsQ6myisFQAGBbwpXWa578QeVxbGQ1SpsgjrW8sA0FqdgigvWvdEKRsyen5o56prGJA4_vbvrQrYUEdmKq8ehjH2PnPJjFECl8fGNAzExGRXJP5p2MstBLsTKfLjj6ohmJhJcfUel0Bxfzc7EW4UY9azDlgMSYusN_UodBAm2y3y4WONJD5kLg1W6uiyMPSivmQzd30EtfL6kziJDAojxiUpZ7hPPk-RrA-ImpaGECx05tNJLJtTRUFXz7ExNWdLFsF3vDabWSGrNPb2j-6dC4MoB0HRCZgDGWGtxZLzBGF8blqpe1kqLiuhaYbU3MPU6RgqtMmyQkx-hRSEmifG3SXHneIN9HgN0mHljgDIELXKxfR-Kb4bYx8NqObCiUnjOIUyRN8hSnPBK_cItgM1qICpiQvkI5fo9oENHOBkZkmHSCVBDtsYNukJbZmOdBYLg4PiHViaaKCJ9V1Cwhe5V2qRYeS60vV5B8VMc3qFcDfzNX8-arjJ6TtLaMuaPjXzhbXO3VagsMeqlEEARb7VMwN_L3GJEHqQwgMPN5n_gGI_jG6dtozGFtK11gCPqFLGaRXyoAg0K2C1xlJKT4-V-As2akao0_LA9c_aSb-ormFbn1eCCLYJgE9OoMqilVR4AkSo7PX7B5WLRnQAsP_ovHsNMEM0HNFcOQS3q97W_DwSo2Z8slxj2rsYS26qC3xeMlwDUC6x9WgOzI-uC9gCJTU4nfMpPK_3lJ0LahRzNi-AhrmQnarryIncxoHICC5NRbBrU87IQzW6w9QbnFaMsKrxTxFT0MxfETMghcbwenhDK2n3uM7seJGYPXcvfOezn_gP1QOD0iyynDERmlAloXi17wTCG_LhAFuhmfgdwVUHbZHe4F8gnqERphxz_dZ_fb1yeHyv_ACFVHg6d5VqZraRsPyUTMbuF6tQ0zofs4EYV_CG74kZxCUcFq2udlvEIbnQkTris-O2ZK7wEkGqZfakFURA=\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IxhavMh3BQwfHUx7l8tzTLaFUWVN_Nb0f2WK2erSciWPw7CN2vjboVsOSklbo6jNPOBAu_1MtSQP4D7X-RKftZDiLK1kZgPW0SrtkOK8g6W09de_QdymQIYOM9lSqh9ChYN_v2HY0zf1RRGu0XRYiUYHZi7tFsXEVEsCE0v0MlrbHYTsTMJEHwbpurwv1ZHVdTK6fh7hgWaVnr43cGuyK8AFwL01JSdSUr6VU-tRDJ6pw4WOdsNOSjbo4A8qDEevIRnjMXZHSKFeeBthk2DZq9A9XkiQUo88z0FwqwFhlTSrzpI5p7qa69GLXBznX8m9XMlYORxA4TOCmAJ1mIHfcHIztlcX7x9Eb0EX_R0R3vgkBZIwP0rhaZzijD1Pqjd-JXxIFjr5L_CY8nhBNL3BCGIqgbnURN31Z0BPbJ44qYSkdBHDD84fajmYOeR6e3GkYlB7yHNZ87vMvLWgyPF81GzUuzZ9BF0SqfTyIJbUa1ZXT5i0VwEJ9fCCmBZK3ouvPxkuch2u2Fl80t31PeO58XMcggQl9ZRx2yFUM0zSVxMMTxuV0nsn9OSAAxwK-2UHohnuF8y_uWMYLa2vTsQqF4mwjsWlt5YsvFtrPfbAXABdrQKaAM_ui1fuSVnAHNNqYsFBIbnw68c7mLrydpzZWsx8kHx8pSmRwC_V4wwo_AQFtW3FwVgCsL6988gZ4XnEX-pw9bsOKIyCB2PSxfjoqMDEIbxIoDl9z92q9PsPxmdgdHuxuA22jSDmPy8qzbBKaX0NG088X8CEpSg6hLtIjON4rk-uFXQD5I9ZlAcpTYlARA_U1SkFDzwfnBUuYD1_Qqdv-YC0L_hRfnR6gABwfvnl_neyqX2J7wuZTWFmx5t3oCgPZhy1N1KHx4S1vGjsc2Qu7LRtKEC70Rk2Y2de0CIREuWp2ddcF5dVq4JjNuPzdVfsq1fWLTL33YtTaLJhDJigAkCVWkjMeUz8rTHplIR79ilx1yp4Dwf2irPWLHCJGHGOdxrBXLxwmlTP3kfoLeicSmblmQZ6pTKlyoD7WfqjWIoRYz_YD2cam9ga7fo9JNXwLsAfOAJ7yFXn_js7Zmjelbz_Wa9ZdvPTbSWYaPMfUoAZfx_FZOELlYy6lHfR1CmkZrt5GeruIrWMg_TliarCxSxEmTDwEEybDwwAV7LzzDLyiCbdndxrpfGgi7Lp5JPjb3FpoDIcU6RcKgG147EZsfeQQUXGbkEuOwl_dNdZ9HRzHWaIqfM9ZYm-UlNup0XuXoHPuYy25qyRjQtZ7aJ2WbJQKh-82qG0lV0cV7jHwDmKk2zXe2d4JD_nqcm-ZsoVP2BOG-87mcH1dSxVHmSMyJKtSxrmmRt20ZcUkuU7eJmj7_dP5W8KLEfT7cb7-DExpgdMuM_4nkUCriyS_tmA0RkImpHptEQjMxITKZz4FpDH7K38ZGNW7hZEdTH0UnhgMNEEVPMDZYSesbHP\" rel=\"nofollow\" target=\"_blank\"><u>Twitter<\/u><\/a>.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GLi1TAOcykzcmnrG1GHwdNnsu7kG7KspW1e0p6MJ5LC4Q5zXo-MwyP_P3JOAALl_tKCJ0wQcMczzZPxC9iJE93DuZ226i-jpYp4C1pguMBM69xDFFxJi0q20-VBV11Cde9p2qvPVxJBoJwFSwGIsbZUcdy4BZDbykzIK8Idos73dQhNhBprkB5rIYZ8lzNnBtPe2zk3__Dyqet156YU5b9avYEv_yKNSoOdXPEFJ8Y-dpAjTHEMcyJCJnUMusI6U5tF16XIpGLmy3gjf-YMUNPvLBkyxnpYCCCxW3hB_xXGjzl7exLYkJdn3T6BJe0TQuf8A8KA31nfCo7CAuj_tBP0u--Ia3sgXR3XeZ-EnWAu6TWsfqtQWDfryBT2Kb5MJ03oxL38bfLkX3R_E2QPou3wERqQBetp7jQdz0_wiMqR4p00K9PBErAj59V0i-7BV9oMAIMMOCwPWDYVAPg4lOQ==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>View source version of release on GlobeNewswire.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Contacts:<\/strong>\u00a0<br \/>Celcuity Inc.\u00a0<br \/>Brian Sullivan, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CVsAXSWXHAdy1CiHQ8-o7l6JgB3fAwoormQRrpCYdOaJ0A-Jn6mBzHc5co1-Rf8574o06hhwOHd3c4pRi7GFNU6qcajwECQElsYCnWTNPuw=\" rel=\"nofollow\" target=\"_blank\"><u>bsullivan@celcuity.com<\/u><\/a>\u00a0<br \/>Vicky Hahne, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y7dbmXJQ2YTPEkpfVZbqHUiRTYFBbs53N0TnYQOLy6y5boKXix4ncWJruXr9LzbpaLAsa61Ox6nAjTLC6Mz62dj8CpRvoQrgcGjW5I4q04g=\" rel=\"nofollow\" target=\"_blank\"><u>vhahne@celcuity.com<\/u><\/a>\u00a0<br \/>(763) 392-0123\u00a0<\/p>\n<p>ICR Healthcare<br \/>Patti Bank,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xMXI_cfbp9YXy60iAqD21UECVcbJ3Aj05eWZjGILTDw3Orsdkt94dAYoucFDzil8Z6-LizuJB6_PI7II3IshO4PCSqy9x0EghzlO6OvJlIEskZ-mDdWSgMVGH7CBWLkx1s1iHvlv7gByPkiyPb9lMSd_VA4t041hjFGurBWirfEM95s2a17U6UHafKSFoy5wcCTE_NsKHc1zWvc-i5-2n5SRVb2zG2vdRR8CmQdNd9ysYT7i4GJX9x-nDCMvMUKDc2M360AdN1d8rzh929ccO40SVVJOgWsZ7tCx-QAr55SOz1rD5NZgxRpmeZ7rkieF\" rel=\"nofollow\" target=\"_blank\"><u>patti.bank@icrhealthcare.com<\/u><\/a><br \/>(415) 513-1284<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGI5NDVjNGQtNGY0MS00N2RmLWFkODUtZGVhYjYxNTQzOTQyLTExNjg1NzMtMjAyNS0wNC0wMS1lbg==\/tiny\/Celcuity-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/stifel99\/celc\/2065375; and A fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/needham146\/celc\/2212811. Alternatively, the live webcasts will be accessible from the Investors section &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celcuity To Present at Upcoming Needham and Stifel Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832239","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/stifel99\/celc\/2065375; and A fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/needham146\/celc\/2212811. Alternatively, the live webcasts will be accessible from the Investors section &hellip; Continue reading &quot;Celcuity To Present at Upcoming Needham and Stifel Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-01T11:26:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences\",\"datePublished\":\"2025-04-01T11:26:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/\"},\"wordCount\":366,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/\",\"name\":\"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=\",\"datePublished\":\"2025-04-01T11:26:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - Market Newsdesk","og_description":"MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/stifel99\/celc\/2065375; and A fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/needham146\/celc\/2212811. Alternatively, the live webcasts will be accessible from the Investors section &hellip; Continue reading \"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-01T11:26:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences","datePublished":"2025-04-01T11:26:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/"},"wordCount":366,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/","name":"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=","datePublished":"2025-04-01T11:26:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDQ4MSM2ODQ0MjI2IzIxNTcwMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celcuity To Present at Upcoming Needham and Stifel Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832239"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}